The present invention relates to an expression cassette for a target protein, comprising a promoter, a polynucleotide coding for the target protein, an intron sequence, and a poly A sequence, an expression vector, and a transformant. The expression cassette for a target protein according to the present invention can simultaneously perform the expression of the intron sequence and the target protein through one transduction and exhibits the effect of inducing the high expression and high functionality of the target protein by regulating the expression of an endogenous gene.
The present invention relates to a method for treating TNFα-related diseases by subcutaneously administering an antibody (anti-TNFα antibody) that binds to TNFα or an antigen-binding fragment thereof. A treatment method, a composition, a kit, or a use according to the present invention provides the advantage that administration time is reduced compared to intravenous injections and the amount of time that patients stay in hospitals is reduced, and thus patient satisfaction is increased through improved convenience and improved quality of life. In particular, the present invention has the advantage of providing a therapeutic agent that is highly effective in improving medication convenience, disease treatment effects, growth disorders, and the like with respect to pediatric/adolescent patients suffering from autoimmune diseases.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceutical preparations for
the treatment of osteoporosis; pharmaceutical products for
the treatment of bone diseases; pharmaceutical preparations
for the treatment of bone loss; pharmaceutical preparations
for increasing bone density.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for cancer; pharmaceutical preparations for rheumatoid arthritis; pharmaceutical preparations for the treatment of inflammations; pharmaceutical preparations for the treatment of transplant rejection; pharmaceutical preparations for the treatment of autoimmune disorders; pharmaceutical preparations for the treatment of infectious diseases
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for the treatment of bone loss; pharmaceutical preparations for increasing bone density.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for the treatment of bone loss; pharmaceutical preparations for increasing bone density.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations of therapeutic and monoclonal antibodies for the treatment of cancer
Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
15.
PHARMACEUTICAL COMPOSITION CONTAINING AZILSARTAN FOR TREATING HYPERTENSION
The present invention relates to a pharmaceutical composition containing azilsartan as an active ingredient for treating hypertension. More specifically, the present invention relates to a pharmaceutical composition for treating hypertension, which includes azilsartan, an active metabolite of azilsartan medoxomil, and is administered in a novel dosage that ensures bioequivalence with azilsartan medoxomil formulations.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A stable pharmaceutical formulation according to the present invention comprises: (A) an antibody or antigen-binding fragment thereof that binds to interleukin-17A (IL-17A); (B) a surfactant; (C) a stabilizer; (D) a buffer; and (E) an antioxidant. The present invention also comprises a pharmaceutical formulation prepared by a step of filling a container with nitrogen and a venting and nitrogen filling step when a rubber stopper is inserted into a pre-filled syringe, in manufacturing a drug product. The stable pharmaceutical formulation according to the present invention has low viscosity even when the formulation comprises an antibody, particularly an antibody in a large amount, has excellent long-term storage stability on the basis of excellent stability under accelerated and harsh conditions, and can be administered intravenously or subcutaneously.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
21.
METHOD AND DEVICE FOR ENVIRONMENTAL AND UTILITY MONITORING OF PHARMACEUTICAL PRODUCTION FACILITY
A method for environmental and utility monitoring of a pharmaceutical production facility according to one embodiment of the present invention comprises the steps of: generating a sampling schedule for environmental and utility monitoring; assigning a sampler and a sampling item for a monitoring task corresponding to the sampling schedule; receiving information about environmental and utility sampling performed on the basis of the sampling schedule; and receiving a request for the culture of a specimen corresponding to the sampling.
G06Q 10/06 - Ressources, gestion de tâches, des ressources humaines ou de projetsPlanification d’entreprise ou d’organisationModélisation d’entreprise ou d’organisation
G05B 19/418 - Commande totale d'usine, c.-à-d. commande centralisée de plusieurs machines, p. ex. commande numérique directe ou distribuée [DNC], systèmes d'ateliers flexibles [FMS], systèmes de fabrication intégrés [IMS], productique [CIM]
22.
EXPRESSION CASSETTE INCLUDING INTRON FOR HIGH EXPRESSION OF PROTEIN OF INTEREST AND USE THEREOF
The present invention relates to an expression cassette comprising an intron, for high expression of a protein of interest, and use thereof. More particularly, the present invention relates to an expression cassette comprising an intron sequence, a vector and transformant including same, and a method for preparing a protein of interest using same. The protein-of-interest expression cassette according to the present invention has the effect of inducing high expression of a protein of interest through a single transduction.
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of auto-immune
diseases; pharmaceutical preparations for the treatment of
psoriasis; pharmaceutical preparations for the treatment of
arthritis; pharmaceutical preparations for treating Crohn's
disease; pharmaceutical preparations for the treatment of
inflammatory diseases; drugs for medical purposes;
pharmaceuticals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for respiratory organs; allergy
medications; immunizing agent; immunosuppressive drug;
pharmaceutical preparations for treating asthma;
pharmaceutical preparations for treating chronic urticaria;
pharmaceutical preparations for the treatment of chronic
rhinosinusitis.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of auto-immune
diseases; pharmaceutical preparations for the treatment of
psoriasis; pharmaceutical preparations for arthritis
treatment; pharmaceutical preparations for treating Crohn
disease; pharmaceutical preparations for the treatment of
inflammatory diseases; drugs for medical purposes;
pharmaceuticals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for respiratory organs; allergy
medications; immunizing agent; immunosuppressive drug;
pharmaceutical preparations for treating asthma;
pharmaceutical preparations for treating chronic urticaria;
pharmaceutical preparations for the treatment of chronic
rhinosinusitis.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of auto immune diseases and autoimmune disorders; pharmaceutical preparations of therapeutic and monoclonal antibodies for the treatment of autoimmune diseases and autoimmune disorders
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders.
The present invention relates to a tablet characterized by a coating layer that includes both an adsorbent and an encapsulating agent in a general coating agent, whereby the tablet significantly improves the odor shielding function caused by medoxomil groups to enhance patient medication compliance.
The present invention relates to an immunogenic composition including multivalent pneumococcal polysaccharide-protein conjugates. Each conjugate includes capsular polysaccharides of different pneumococcus serotypes conjugated to a carrier protein. More concretely, the present invention is a multivalent immunogenic composition including polysaccharide-protein conjugates. Each of the polysaccharide-protein conjugates includes Streptococcus pneumoniae-derived capsular polysaccharides of different serotypes conjugated to a carrier protein. The capsular polysaccharides include a) capsular polysaccharides of one or more serotypes selected from the group consisting of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and b) capsular polysaccharides of one or more serotypes selected from the group consisting of serotypes 10A, 11A, 12F, 15B, 22F, 23A, and 35B. The multivalent immunogenic composition according to the present invention is capable of inducing an immune reaction against a wider variety of serotypes than the conventional Prevenar 13. In particular, the conventional Prevenar 13 is designed mainly for serotypes frequently appearing in Europe and North America, but the immunogenic composition of the present invention is an immunogenic composition having high coverage not only in Europe and North America but also throughout Asia. Therefore, the multivalent immunogenic composition according to the present invention is capable of being beneficially used to prevent diseases caused by pneumococcus in infants, children, and adults.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of auto-immune
diseases; pharmaceutical preparations for the treatment of
psoriasis; pharmaceutical preparations for the treatment of
arthritis; pharmaceutical preparations for the treatment of
crohn's disease; pharmaceutical preparations for the
treatment of inflammatory diseases.
38.
STABLE PHARMACEUTICAL FORMULATION, VIAL, CARTRIDGE, PRE-FILLED SYRINGE AND AUTO-INJECTOR COMPRISING THE SAME
The stable pharmaceutical formulation according to the present disclosure comprises (A) an antibody or antigen-binding fragment thereof that binds to an interleukin-6 receptor; (B) a surfactant; (C) stabilizers; and (D) a buffer. The stable pharmaceutical formulation according to the present disclosure has a low viscosity even when it contains an antibody, especially at a high concentration, and has excellent long-term storage stability based on excellent stability under accelerated and severe conditions, and may be administered intravenously or subcutaneously.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A stable pharmaceutical formulation according to the present disclosure contains: a recombinant fusion protein; a surfactant; a sugar or a derivative thereof; a buffer; and an isotonic agent. The stable pharmaceutical formulation according to the present disclosure has low viscosity while containing the recombinant fusion protein, may maintain excellent stability under long-term storage conditions, accelerated conditions and stress conditions, and may be administered intraocularly.
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of auto-immune
diseases; pharmaceutical preparations for the treatment of
immune system related diseases and disorders.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for treating respiratory organs; allergy medications; immunizing agent, namely, pharmaceutical preparation for the treatment of immune system related diseases and disorders; immunosuppressant pharmaceutical preparations; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating chronic urticaria
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of psoriasis; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of crohn's disease; pharmaceutical preparations for the treatment of inflammatory diseases.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of psoriasis; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of crohn's disease; pharmaceutical preparations for the treatment of inflammatory diseases
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders
The present invention relates to a method for expressing a target protein and, more specifically, to: a signal peptide for secreting a target protein into the periplasm; a nucleic acid encoding same; an expression vector comprising the nucleic acid; a recombinant microorganism into which the expression vector is introduced; and a method for expressing a target protein by using the recombinant microorganism. The prevention invention allows a target protein to be properly expressed in E. coli and improves secretion efficiency into the periplasm. Therefore, the method for expressing a target protein, according to the present invention, enables high-yield protein production.
C07K 14/34 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Corynebacterium (G)
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Reagent paper for inspection (other than for medical or
veterinary purposes); china clay; by-products of the
processing of cereals for industrial purposes; chemicals
used in industry/science and photography as well as in
agriculture/ horticulture and forestry; artificial
sweeteners used in industry; chemicals and adhesives used in
industry; cell growth media for growing cells for use in
scientific research; cells for scientific or laboratory
purposes; ceramic glazings; unprocessed artificial resin;
antifreezing liquids; birdlime; biological preparations for
use in biotechnology [other than medical]; biological tissue
cultures, other than for medical or veterinary purposes;
biological preparation for use in cell cultures other than
for medical or veterinary use; hydraulic oils; metalloids;
stem cells, other than for medical or veterinary purposes;
compositions for the manufacture of technical ceramics;
chemical pulp. Deodorizing preparations for household, commercial or
industrial use; mothproof paper; insecticides; dietary
supplements; first aid boxes sold filled; food for babies;
microorganisms (preparations of -) for medical and
veterinary use; medicated diapers; medical and surgical
plasters; culture media for medical use; biological tissue
cultures for medical purposes; cells for medical purposes;
drugs for medical purposes; milk sugar for medical purposes
[lactose]; diagnostic preparations for medical purposes;
adhesive skin patches for medical use; antibodies for
medical purposes; surgical implants grown from stem cells
[living tissues]; abrasives (dental -); fly glue. Research in relation to technology for construction
purposes; architectural services; development of engineering
products; scientific research; testing, inspection and
research services in the fields of agriculture, livestock
breeding and fisheries; development of biotechnology; drug
discovery services; information technology services provided
on an outsourcing basis; pharmaceutical research and
development; testing, inspection and research services in
the fields of pharmaceuticals, cosmetics and foodstuffs;
medical laboratories; dress design services; analysis and
evaluation of medical product development; product design;
design and development of computers and programs for
computers; design, maintenance, rental and updating of
computer software; development of computer hardware; marine,
aerial and land surveying; cosmetic research; research in
the field of environmental conservation and protection.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Reagent paper for inspection (other than for medical or
veterinary purposes); china clay; by-products of the
processing of cereals for industrial purposes; chemicals
used in industry/science and photography as well as in
agriculture/ horticulture and forestry; artificial
sweeteners used in industry; chemicals and adhesives used in
industry; cell growth media for growing cells for use in
scientific research; cells for scientific or laboratory
purposes; ceramic glazings; unprocessed artificial resin;
antifreezing liquids; birdlime; biological preparations for
use in biotechnology [other than medical]; biological tissue
cultures, other than for medical or veterinary purposes;
biological preparation for use in cell cultures other than
for medical or veterinary use; hydraulic oils; metalloids;
stem cells, other than for medical or veterinary purposes;
compositions for the manufacture of technical ceramics;
chemical pulp. Deodorizing preparations for household, commercial or
industrial use; mothproof paper; insecticides; dietary
supplements; first aid boxes sold filled; food for babies;
microorganisms (preparations of -) for medical and
veterinary use; medicated diapers; medical and surgical
plasters; culture media for medical use; biological tissue
cultures for medical purposes; cells for medical purposes;
drugs for medical purposes; milk sugar for medical purposes
[lactose]; diagnostic preparations for medical purposes;
adhesive skin patches for medical use; antibodies for
medical purposes; surgical implants grown from stem cells
[living tissues]; abrasives (dental -); fly glue. Research in relation to technology for construction
purposes; architectural services; development of engineering
products; scientific research; testing, inspection and
research services in the fields of agriculture, livestock
breeding and fisheries; development of biotechnology; drug
discovery services; information technology services provided
on an outsourcing basis; pharmaceutical research and
development; testing, inspection and research services in
the fields of pharmaceuticals, cosmetics and foodstuffs;
medical laboratories; dress design services; analysis and
evaluation of medical product development; product design;
design and development of computers and programs for
computers; design, maintenance, rental and updating of
computer software; development of computer hardware; marine,
aerial and land surveying; cosmetic research; research in
the field of environmental conservation and protection.
51.
PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION
The present invention relates to a pharmaceutical composition comprising S(−)-cibenzoline or a pharmaceutically acceptable salt thereof as an active ingredient for treatment of hypertrophic cardiomyopathy, and a method for treatment of hypertrophic cardiomyopathy by using same.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Reagent paper for inspection other than for medical or veterinary purposes; china clay; by-products of the processing of cereals for industrial purposes; chemicals used in industry/science and photography as well as in agriculture/ horticulture and forestry; artificial sweeteners used in industry; chemicals and adhesives used in industry; cell growth media for growing cells for use in scientific research; cells for scientific or laboratory purposes; ceramic glazings in the nature of a dry chemical preparation for use in the manufacture of ceramics; unprocessed artificial resin; antifreezing liquids; birdlime; biological preparations for use in biotechnology industry other than medical; biological tissue cultures, other than for medical or veterinary purposes; biological preparation for use in cell cultures other than for medical or veterinary use; hydraulic oils; metalloids; stem cells, other than for medical or veterinary purposes; chemical compositions for the manufacture of technical ceramics; chemical paper pulp All purpose deodorizing preparations for household, commercial or industrial use; mothproof paper; insecticides; dietary supplements; first aid boxes sold filled; food for babies; preparations of microorganisms for medical and veterinary use; medicated baby diapers; medical and surgical plasters; cell culture media for medical use; biological tissue cultures for medical purposes; cells for medical purposes; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparationsfor the treatment of viral diseases; pharmaceutical preparations for the treatment of respiratory diseases; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of dermatological diseases; pharmaceutical preparations for the treatment of cancer and tumor pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for the treatment of metabolic diseases; pharmaceutical preparations for the treatment of endocrine diseases; pharmaceutical preparations for the treatment of genitourinary diseases; pharmaceutical preparations for the treatment of hepatological diseases; pharmaceutical preparations for the treatment of eye diseases; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the treatment of neurological disorders; pharmaceutical preparations for the treatment of cardiovascular disease; milk sugar for medical purposes [lactose]; diagnostic preparations for medical purposes; adhesive skin patches for medical use; antibodies for medical purposes; surgical implants grown from living tissue stem cells; dental abrasives; fly glue Research in relation to technology for construction purposes; architectural services; development of engineering products; scientific research; testing, inspection and research services in the fields of agriculture, livestock breeding and fisheries; development of biotechnology; drug discovery services; outsource service providers in the field of information technology relating to installation, maintenance and repair of computer software; pharmaceutical research and development; testing, inspection and research services in the fields of pharmaceuticals, cosmetics and foodstuffs; medical research laboratories; dress design services; analysis and evaluation of medical product development; new product design; design and development of computers and programs for computers; design, maintenance, rental and updating of computer software; development of computer hardware; marine, aerial and land surveying; cosmetic research; research in the field of environmental conservation and protection
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Reagent paper for inspection other than for medical or veterinary purposes; china clay; by-products of the processing of cereals for industrial purposes; chemicals used in industry/science and photography as well as in agriculture/ horticulture and forestry; artificial sweeteners used in industry; chemicals and adhesives used in industry; cell growth media for growing cells for use in scientific research; cells for scientific or laboratory purposes; ceramic glazings in the nature of a dry chemical preparation for use in the manufacture of ceramics; unprocessed artificial resin; antifreezing liquids; birdlime; biological preparations for use in biotechnology industry other than medical; biological tissue cultures, other than for medical or veterinary purposes; biological preparation for use in cell cultures other than for medical or veterinary use; hydraulic oils; metalloids; stem cells, other than for medical or veterinary purposes; chemical compositions for the manufacture of technical ceramics; chemical paper pulp All purpose deodorizing preparations for household, commercial or industrial use; mothproof paper; insecticides; dietary supplements; first aid boxes sold filled; food for babies; preparations of microorganisms for medical and veterinary use; medicated baby diapers; medical and surgical plasters; cell culture media for medical use; biological tissue cultures for medical purposes; cells for medical purposes; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparationsfor the treatment of viral diseases; pharmaceutical preparations for the treatment of respiratory diseases; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of dermatological diseases; pharmaceutical preparations for the treatment of cancer and tumor; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for the treatment of metabolic diseases; pharmaceutical preparations for the treatment of endocrine diseases; pharmaceutical preparations for the treatment of genitourinary diseases; pharmaceutical preparations for the treatment of hepatological diseases; pharmaceutical preparations for the treatment of eye diseases; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the treatment of neurological disorders; pharmaceutical preparations for the treatment of cardiovascular disease; milk sugar for medical purposes [lactose]; diagnostic preparations for medical purposes; adhesive skin patches for medical use; antibodies for medical purposes; surgical implants grown from living tissue stem cells; dental abrasives; fly glue Research in relation to technology for construction purposes; architectural services; development of engineering products; scientific research; testing, inspection and research services in the fields of agriculture, livestock breeding and fisheries; development of biotechnology; drug discovery services; outsource service providers in the field of information technology relating to installation, maintenance and repair of computer software; pharmaceutical research and development; testing, inspection and research services in the fields of pharmaceuticals, cosmetics and foodstuffs; medical research laboratories; dress design services; analysis and evaluation of medical product development; new product design; design and development of computers and programs for computers; design, maintenance, rental and updating of computer software; development of computer hardware; marine, aerial and land surveying; cosmetic research; research in the field of environmental conservation and protection
The present invention relates to a crystal form of (−)-Cibenzoline succinate. In addition, the present invention relates to a method for preparing (−)-Cibenzoline succinate having a chiral purity of 99.9% or higher. Additionally, the present invention provides a method for preparing (−)-Cibenzoline succinate and a crystal form thereof.
C07D 233/10 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle avec des radicaux alkyle, contenant plus de quatre atomes de carbone, liés directement aux atomes de carbone du cycle avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement à l'atome d'azote du cycle
56.
VARICELLA ZOSTER VIRUS FUSION PROTEIN AND IMMUNOGENIC COMPOSITION COMPRISING SAME
The present invention relates to a Varicella zoster virus fusion protein and an immunogenic composition comprising same and, more specifically, to a fusion protein comprising the glycoprotein E (gE) of Varicella zoster virus (VZV) and a constant region of an immunoglobulin molecule, and an immunogenic composition comprising same. The present invention not only remarkably increases a Varicella zoster virus-specific cell-mediated immune response, but also exhibits the effect of rapidly and potently inducing an immune response and sustaining the immune response for a long period of time, compared to preexisting vaccines, thereby can be usefully used to prevent Varicella zoster-related diseases.
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès
57.
BINDING MOLECULE HAVING NEUTRALIZING ACTIVITY AGAINST SARS-CORONAVIRUS-2
KOREA DISEASE CONTROL AND PREVENTION AGENCY (République de Corée)
Inventeur(s)
Kim, Cheol-Min
Seo, Ji-Min
Kim, Min-Soo
Lee, Soo-Young
Ryu, Dong-Kyun
Kim, Sung-Soon
Lee, Joo-Yeon
Kim, Kyung-Chang
Yang, Jeong-Sun
Lee, Han-Saem
Woo, Hye-Min
Kim, Jun-Won
Abrégé
The present invention relates to a binding molecule that binds to SARS-coronavirus-2 (SARS-CoV-2). More particularly, the binding molecule of the present invention has strong ability to bind to a spike protein (S protein) on the surface of SARS-coronavirus-2 and high neutralizing activity against SARS-coronavirus-2 and is thus very useful in the diagnosis, prevention or treatment of SARS-coronavirus infection (COVID-19).
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
58.
STABILITY-IMPROVED PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DIABETES MELLITUS
The present invention relates to a pharmaceutical composition for treatment of diabetes mellitus, with improved stability and, more specifically, to a pharmaceutical composition comprising a core containing metformin or a salt thereof, a drug coat layer containing alogliptin or a salt thereof, and a shielding coat layer therebetween, whereby the problem of the stability reduction attributed to the contact between the two ingredients is solved.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceuticals; drugs for
medical purposes; preparations for the treatment of
arthritis; pharmaceutical preparations for suppressing
cytokine; preparations for the treatment of arteritis;
pharmaceutical preparations for the treatment of lung
diseases; pharmaceutical preparations for immunity
adjustment; monoclonal antibodies for medical purposes;
preparations for the treatment of auto-immune diseases.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceutical preparations for
the treatment of osteoporosis; pharmaceutical products for
the treatment of bone diseases; pharmaceutical products for
the treatment of bone loss; drugs for increasing bone
density.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceutical preparations for
the treatment of osteoporosis; pharmaceutical products for
the treatment of bone diseases; pharmaceutical products for
the treatment of bone loss; drugs for increasing bone
density.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceuticals; drugs for
medical purposes; preparations for the treatment of
arthritis; pharmaceutical preparations for suppressing
cytokine; preparations for the treatment of arteritis;
pharmaceutical preparations for the treatment of lung
diseases; pharmaceutical preparations for immunity
adjustment; monoclonal antibodies for medical purposes;
preparations for the treatment of auto-immune diseases.
The present invention relates to a crystalline form of (−)-cibenzoline succinate. The present invention also provides a process for preparing (−)-cibenzoline succinate and a crystalline form thereof. The crystalline form of (−)-cibenzoline succinate according to the present invention has low hygroscopicity, and excellent stability under accelerated conditions and long-term storage conditions, and may be stably maintained without a change in content thereof for a long period of time.
C07D 233/10 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle avec des radicaux alkyle, contenant plus de quatre atomes de carbone, liés directement aux atomes de carbone du cycle avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement à l'atome d'azote du cycle
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of cancer, of oncological diseases and disorders, and of proliferative disorders, namely, angiogenic disorders, cancer; antibodies for medical purposes for the treatment of cancer; drugs for medical purposes for the treatment of cancer
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of bone loss.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of COVID-19; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for suppressing cytokine; pharmaceutical preparations for the treatment of arteritis; pharmaceutical preparations for the treatment of lung diseases; pharmaceutical preparations for use in the treatment of immunological disorders; pharmaceutical preparations for the treatment of auto-immune diseases.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of bone diseases and disorders, oncological and metabolic diseases and disorders and complications associated therewith, and hypercalcemia of malignancy; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for the treatment of tumours
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of bone loss; drugs, namely, pharmaceutical preparations for increasing bone density
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of bone loss; drugs, namely, pharmaceutical preparations for increasing bone density
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of bone loss.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of COVID-19; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for suppressing cytokine; pharmaceutical preparations for the treatment of arteritis; pharmaceutical preparations for the treatment of lung diseases; pharmaceutical preparations for use in the treatment of immunological disorders; pharmaceutical preparations for the treatment of auto-immune diseases.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of bone diseases and disorders, of oncological and metabolic diseases and disorders and complications associated therewith, and of hypercalcemia of malignancy; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for the treatment of tumours
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations, namely, immunosuppressants, pharmaceutical preparations for the treatment of COVID-19, and anti-interleukin-6 (il-6) receptor monoclonal antibody for the treatment of disease caused by il-6 production; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for suppressing cytokine; pharmaceutical preparations for the treatment of arteritis; pharmaceutical preparations for the treatment of lung diseases; pharmaceutical preparations for immunity adjustment; monoclonal antibodies for medical purposes; pharmaceutical preparations for the treatment of auto-immune diseases
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of pain, of COVID-19, and anti-interleukin-6 (il-6) receptor monoclonal antibody for the treatment of disease caused by il-6 production; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for suppressing cytokine; pharmaceutical preparations for the treatment of arteritis; pharmaceutical preparations for the treatment of lung diseases; pharmaceutical preparations for immunity adjustment; monoclonal antibodies for medical purposes; pharmaceutical preparations for the treatment of auto-immune diseases
79.
Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof
A pharmaceutical formulation including an immediate release layer and an extended release layer according to the present disclosure has a biphasic dissolution profile, such that it is possible to quickly reach an effective plasma concentration of cibenzoline at the early stage, and the effective plasma concentration may be continuously maintained at the late stage. Therefore, the medicinal effect of cibenzoline may be maintained only by an administration of a single formulation once a day.
Injection device for pharmaceuticals; medical instruments;
syringes for medical purposes; medical apparatus; syringes
for injection of medical substances; automatic medical
apparatus for dosing humans by injection; infusion apparatus
for therapeutic purposes; syringes for medical purposes, in
the shape of pens; hypodermic injection apparatus; liquid
medicine syringes; injectors for medical purposes; medical
injection syringe; syringes for injections; medication
injectors; hypodermic syringes.
Injection device for pharmaceuticals; medical instruments;
syringes for medical and infusion purposes; medical
apparatus; syringes for injection of medical substances;
automatic medical apparatus for dosing humans by injection;
infusion apparatus for therapeutic purposes; syringes in the
nature of pens; hypodermic injection apparatus; liquid
medicine syringes; injectors for medical purposes; medical
injection syringe; syringes for injections; medication
injectors; hypodermic syringes.
82.
COMPOSITION COMPRISING AT LEAST TWO SARS-CORONAVIRUS-2-NEUTRALIZING BINDING MOLECULES
The present invention relates to a composition comprising at least two SARS-coronavirus-2-neutralizing binding molecules, and, particularly, to a composition comprising at least two neutralizing binding molecules which specifically bind to a specific epitope in an RBD of a spike protein on the surface of SARS-coronavirus-2. The composition of the present invention has an excellent binding ability and exhibits an excellent neutralizing effect on various coronavirus types and, thus, is very useful for diagnosing, preventing, or treating a disease occurring due to a coronavirus.
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61P 31/14 - Antiviraux pour le traitement des virus ARN
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present invention relates to a SARS-coronavirus-2-neutralizing binding molecule that binds to the epitope of a SARS-coronavirus-2 S protein. A binding molecule according to the present invention has excellent binding ability to wild-type SARS-coronavirus-2 (SARS-CoV-2) and mutant viruses that could occur in the future and to various coronavirus species plausible to infect humans, such as SARS-coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and the like, which can infect humans to cause fatal diseases, and exhibits excellent neutralization effects, and thus is very useful in the diagnosis, prevention or treatment of diseases caused by coronaviruses.
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61P 31/14 - Antiviraux pour le traitement des virus ARN
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations, namely, immunosuppressants; pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of COVID-19, pharmaceutical preparations for the treatment of arteritis, pharmaceutical preparations for suppressing cytokines, pharmaceutical preparations for the treatment of lung diseases, pharmaceutical preparations for immunity adjustment, pharmaceutical preparations for the treatment of auto-immune diseases
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceuticals; drugs for
medical purposes; pharmaceutical products for the treatment
of cancer; antibodies for medical purposes.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceuticals; drugs for
medical purposes; pharmaceutical products for the treatment
of cancer; antibodies for medical purposes.
89.
SARS-CORONAVIRUS-2 FUSION PROTEIN AND IMMUNOGENIC COMPOSITION COMPRISING SAME
The present invention relates to a SARS-coronavirus-2 fusion protein and an immunogenic composition comprising same and, more specifically, to a fusion protein comprising a spike protein (S protein) of SARS-coronavirus-2 (SARS-CoV-2) and a constant region of an immunoglobulin molecule, and an immunogenic composition comprising same. The present invention can induce the production of an SARS-coronavirus-2-specific neutralizing antibody as well as remarkably increasing cell-mediated immune responses. Accordingly, the present invention can not only give rise to an immune response to mutant viruses, but also exhibit a long-term sustainable effect, thus finding advantageous applications in preventing SARS-coronavirus infections (COVID-19).
The present invention relates to an immunogenic composition comprising multivalent Streptococcus pneumoniae polysaccharide-protein conjugates. Each conjugate comprises a capsular polysaccharide of a different Streptococcus pneumoniae serotype conjugated to a carrier protein. More specifically, the present invention includes a multivalent immunogenic composition in which each conjugate comprises a capsular polysaccharide derived from a different Streptococcus pneumoniae serotype conjugated to a carrier protein, wherein the capsular polysaccharide comprises a) a capsular polysaccharide of any one or more serotypes selected from the group consisting of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, and b) a capsular polysaccharide of any one or more serotypes selected from the group consisting of serotypes 10A, 11A, 12F, 15B, 22F, 23A and 35B. Compared to a conventional Prevenar13, the multivalent immunogenic composition according to the present invention can induce immune responses to more diverse serotypes. In particular, the conventional Prevenar13 was designed mainly for frequently occurring serotypes in Europe and North America, whereas the immunogenic composition according to the present invention has high coverage in Europe and North America, and all over Asia. Therefore, a multivalent immunogenic composition according to the present invention can be effectively used in preventing diseases caused by Streptococcus pneumoniae in infants, children and adults.
The present invention relates to a clinical supplies management method performed by a clinical supplies management device for contributing to the invigoration of investigator-initiated clinical trials by effectively managing clinical supplies by means of an online platform such that major parties related to clinical trials can efficiently execute the clinical trials, and by enabling clinical trial personnel (investigators, subjects of clinical trial execution and supervision) such as university hospital professors to proactively manage the provision of the clinical supplies. The method comprises the steps of: registering users related to the clinical trials according to user types; receiving a request for provision of the clinical supplies related to the clinical trials; receiving provision completion information of the clinical supplies; and updating clinical supplies information corresponding to the provision completion information.
G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p. ex. pour la gestion du personnel hospitalier ou de salles d’opération
G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
G06Q 10/08 - Logistique, p. ex. entreposage, chargement ou distributionGestion d’inventaires ou de stocks
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for the treatment of COVID-19; pharmaceutical preparations for the treatment of viral diseases, namely, influenza, norovirus, herpes, hepatitis, and Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of immune diseases, namely, rheumatoid arthritis, Crohn's disease, colitis, and lupus; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases, and inflammatory skin diseases; pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases and treatment of acne; pharmaceutical preparations for the treatment of psoriasis; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of spondylitis; pharmaceutical preparations for the treatment of Multiple Sclerosis; pharmaceutical preparations for the treatment of cancer and tumor; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, and anemia; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders, and neuromuscular diseases, namely primary periodic paralysis; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, and inflammatory pelvic diseases; pharmaceutical preparations for the treatment of hepatological diseases and disorders; pharmaceutical preparations for the treatment of eye diseases; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for the treatment of Genetic disorders; pharmaceutical preparations for the treatment of neurological disorders, namely Alzheimer's, Huntington's Disease, cerebral palsy and seizure disorders.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of COVID-19, pharmaceutical preparations for the treatment of viral diseases, pharmaceutical preparations for the treatment of respiratory diseases, pharmaceutical preparations for the treatment of auto-immune diseases, pharmaceutical preparations for the treatment of immune diseases, pharmaceutical preparations for the treatment of inflammatory diseases, pharmaceutical preparations for use in dermatological diseases, pharmaceutical preparations for the treatment of psoriasis, pharmaceutical preparations for the treatment of arthritis, pharmaceutical preparations for the treatment of spondylitis, pharmaceutical preparations for the treatment of Multiple Sclerosis, pharmaceutical preparations for the treatment of cancer and tumor, pharmaceutical preparations for the treatment of digestive diseases, pharmaceutical preparations for the treatment of metabolic diseases, pharmaceutical preparations for the treatment of endocrine diseases, pharmaceutical preparations for the treatment of genitourinary diseases, pharmaceutical preparations for the treatment of hepatological diseases, pharmaceutical preparations for the treatment of eye diseases, pharmaceutical preparations for the treatment of musculoskeletal disorders, pharmaceutical preparations for the treatment of genetic disorders, pharmaceutical preparations for the treatment of neurological disorders
The present prevention relates to methods for treating TNFα-related diseases by subcutaneously administering an antibody binding to TNFα (anti-TNFα antibody) or an antigen-binding fragment thereof. The treatment method, composition, kit or use according to the present invention provide an advantage of improving patient satisfaction, by improving convenience and quality of life, that is, by reducing the time required for administration and decreasing the length of stay of patients in a hospital compared to intravenous injection.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for treating respiratory organs; allergy medications; immunizing agent, namely, pharmaceutical preparation for the treatment of immune system related diseases and disorders; immunosuppressant pharmaceutical preparations; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating chronic urticaria
